Clinical Trial

A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

Study acronym: CaDAnCe-302
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to investigate the efficacy and safety of BGB-16673 compared with investigator's choice (idelalisib plus rituximab \[for CLL only\] or bendamustine plus rituximab or venetoclax plus rituximab retreatment) in participants with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) previously exposed to both BTK inhibitors (BTKi) and BCL2 inhibitors (BCL2i).
Protocol Amendment History 3 changes
notable Trial sites expanded: 124 -> 127 locations 2026-08-08
notable Trial sites expanded: 120 -> 123 locations 2026-07-10
notable Trial sites expanded: 117 -> 120 locations 2026-06-23
Trial Details
NCT Number NCT06846671
Lead Sponsor BeOne Medicines
Conditions CLL, Chronic Lymphocytic Leukemia
Enrollment 250 participants
Start Date 2025-04-10
Primary Completion 2028-05-15 (estimated)
Study Completion 2030-02-14 (estimated)
Updated on ClinicalTrials.gov 2026-08-07